Macrogen

Macrogen, Inc.
Public
Traded as KRX: 038290
Founded 1997 (1997)
Founder Jun-Seong Seo
Headquarters Seoul, South Korea
Area served
 global
Key people
 Hyonyong Chong (CEO, 2015)
Products
  • DNA sequencing
  • Bioinformatic analysis
Divisions
  • Macrogen Korea
  • Macrogen Japan
  • Macrogen Europe
  • Macrogen USA
Website www.macrogen.com/eng/

Macrogen, Inc. is a South Korean public biotechnology company.[1] The company's headquarters are located in Seoul.[2] The company was founded in 1997 by Jun-Seong Seo,[note 1] a professor at Seoul National University.[3] It was venture capital-backed until its initial public offering (IPO) and subsequent listing on the KOSDAQ market in 2000, making it the first Korean biotechnology firm to raise funds through an IPO.[1][3] The company announced plans in 2010 to map the "Korean genome" based on the notion that United States-backed genome mapping efforts up to that time were representative of the "Caucasian genome" rather than the "Human genome" as claimed.[4] By 2015, the company was described by one news outlet as "a global leader in personalized genomic medicine".[5]

Business model

Macrogen's business model focuses on providing research services to other firms engaged in biotechnology research and development.[3] As of 2005, 50% of the firm's revenue was derived from DNA sequencing services.[3] Prior to its 2000 IPO, the company aimed to be the low-cost leader in providing research services; after the IPO, Macrogen turned to DNA sequencing technology development as a way to distinguish itself from competitors.[3] As of 2015, the company had four main divisions based on geography: Korea, USA, Europe and Japan.[6]

Consistent with the post-IPO competitive technology strategy was Macrogen's being among the first customers to purchase a HiSeq X Ten System from Illumina in January 2014,[7] purported to be the first sequencing system to enable cracking the $1,000 genome boundary.[8]

In 2015, the company underwent a corporate identity revision, which included a revised corporate logo and a revised corporate slogan: "Humanizing Genomics."[5]

Corporate governance

As of 2014, HyungTae Kim held the role of chief executive officer (CEO) at Macrogen.[2] By early 2015, however, the CEO role had been filled by Hyonyong Chong.[5]

With respect to the company's Board, founder Jun-Seong Seo remained Chairman as of 2015.[5]

According to KOSDAQ statistics, over 90% of the company's outstanding stock is held by individual investors.[9]

Strategic and tactical relationships

In late 2014, Macrogen licensed Clarity LIMS from GenoLogics, a system "built specifically for the needs of clinical or research genomics and mass spec laboratories".[7] Initial integration with service offerings was to be through the USA-based Macrogen Clinical Laboratory.[7]

In 2014 and 2015, Macrogen won competitive bidding rounds to provide genome analysis services to the University College London.[10]

Macrogen Corp

Macrogen Corp. was formed to offer top and distinguished clinical sequencing services to U.S. patients and hospitals, under the tutelage and guidance of Macrogen Inc. in late 2012. Based in Rockville, Maryland, Macrogen Corp. provides CLIA-licensed and top quality services through the research and clinical experiences of genetic and medical experts. Macrogen Corp. offers diagnostic testing for genetic diseases through clinical whole-exome sequencing and targeted sequencing, and provides a "total genomic solution" for the clinical and research area. Future service offering include DNA chip-based neo-genome scanning and cancer diagnostic panels, as well as transcriptome sequencing.[11]

References

  1. 1 2 "(unknown)". Korea Now. 31. 2002. Retrieved 2015-07-14 – via Google Books (snippet view).
  2. 1 2 Staff (November 3, 2014). "Macrogen Introduces Latest Service Portfolio and Presents Research Outcome at 2014 ASHG Annual Meeting". Biotech Business Week. Retrieved 2015-07-15 – via HighBeam Research.
  3. 1 2 3 4 5 Wong, Joseph (September 15, 2011). Betting on Biotech: Innovation and the Limits of Asia's Developmental State. Cornell University Press. pp. 97–8. ISBN 0801463386 – via Google Books (preview).
  4. ↑ Sleeboom-Faulkner, Margaret (2010). Frameworks of Choice: Predictive & Genetic Testing in Asia. Amsterdam University Press. p. 28. ISBN 9789089641656 – via Google Books (full view).
  5. 1 2 3 4 Staff (April 15, 2015). "Macrogen Renews CI after 19 Years, Making a Great Leap Forward to Be a Global Leader of Personalized Genomic Medicine". Biotech Week. Retrieved 2015-07-15 – via HighBeam Research.
  6. ↑ "Macrogen". www.macrogen.com. See footer content. Retrieved 2015-07-15.
  7. 1 2 3 Staff (November 4, 2014). "Macrogen Selects GenoLogics' Clarity LIMS to Strengthen X-Genome and Clinical Sequencing Services". Information Technology Newsweekly. Retrieved 2015-07-15 – via HighBeam Research.
  8. ↑ "Illumina Introduces the HiSeq X™ Ten Sequencing System" (Press release). Illumina. January 14, 2014. Retrieved 2015-07-15.
  9. ↑ "Trading Performance by Investor". KRX Korea Exchange. Korea Exchange. Sort table by percent. Retrieved 2015-07-15. 91.84 (in percent field for row with investor value "Individual")
  10. ↑ Staff (June 15, 2015). "Products & Services". News. Genetic Engineering & Biotechnology News. 35 (12). p. 8.
  11. ↑ "About Us". Retrieved 2016-09-14.

Notes

  1. ↑ "Junseong Seo" in one news citation.
This article is issued from Wikipedia - version of the 11/16/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.